nbc news semaglutide In the original clinical trials looking at (the GLP-1 in Novo Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the weight after FDA warns about fake Ozempic

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

Abscisic acid has been shown to enhance insulin secretion and support glucose absorption, stimulating release GLP-1

They drink even more

FDA says cost, convenience, and supply preference do not create a 503B clinical need. Patients should not treat compounded GLP-1 products as FDA-approved generics